Second-generation rabies virus-based vaccine vectors expressing human immunodeficiency virus type 1 Gag have greatly reduced pathogenicity but are highly immunogenic

Journal of Virology

Volumn 77, Issue 1, 2003, Pages 237-244

  McGettigan, James P ^a   Pomerantz, Roger J ^a   Siler, Catherine A ^a   McKenna, Philip M ^a   Foley, Heather D ^a   Dietzschold, B ^a   Schnell, Matthias J ^a,b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; DRUG VEHICLE; GAG PROTEIN; GLUTAMIC ACID; PHOSPHOPROTEIN; RABIES VACCINE; VIRUS VECTOR;

AMINO ACID SUBSTITUTION; ANIMAL EXPERIMENT; ARTICLE; CELLULAR IMMUNITY; DRUG SAFETY; FEMALE; GENETIC TRANSCRIPTION; HEPATITIS C; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNOGENICITY; MORTALITY; MOUSE; NONHUMAN; PATHOGENICITY; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; RABIES VIRUS; VIRUS PARTICLE;

AIDS VACCINES; ANIMALS; ANTIGENS, VIRAL; FEMALE; GENE PRODUCTS, GAG; GENETIC VECTORS; GLYCOPROTEINS; HIV-1; MICE; RABIES VIRUS; VACCINES, ATTENUATED; VACCINES, SYNTHETIC; VIRAL ENVELOPE PROTEINS;

EID: 0037213927     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.77.1.237-244.2003     Document Type: Article

References (34)

1. Adachi, A., H. E. Gendelman, S. Koenig, T. Folks, R. Willey, A. Rabson, and M. A. Martin. 1986. Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J. Virol. 59:284-291.
2. Ball, L. A., C. R. Pringle, B. Flanagan, V. P. Perepelitsa, and G. W. Wertz. 1999. Phenotypic consequences of rearranging the P, M, and G genes of vesicular stomatitis virus. J. Virol. 73:4705-4712.
3. Buchholz, U. J., S. Finke, and K. K. Conzelmann. 1999. Generation of bovine respiratory syncytial virus (BRSV) from cDNA: BRSV NS2 is not essential for virus replication in tissue culture, and the human RSV leader region acts as a functional BRSV genome promoter. J. Virol.73:251-259.
4. Conzelmann, K. K., J. H. Cox, L. G. Schneider, and H. J. Thiel. 1990. Molecular cloning and complete nucleotide sequence of the attenuated rabies virus SAD B19. Virology 175:485-499.
5. Coulon, P., J. P. Ternaux, A. Flamand, and C. Tuffereau. 1998. An avirulent mutant of rabies virus is unable to infect motoneurons in vivo and in vitro. J. Virol. 72:273-278.
6. Dietzschold, B., W. H. Wunner, T. J. Wiktor, A. D. Lopes, M. Lafon, C. L. Smith, and H. Koprowski. 1983. Characterization of an antigenic determinant of the glycoprotein that correlates with pathogenicity of rabies virus. Proc. Natl. Acad. Sci. USA 80:70-74.
7. Etessami, R., K. K. Conzelmann, B. Fadai-Ghotbi, B. Natelson, H. Tsiang, and P. E. Ceccaldi. 2000. Spread and pathogenic characteristics of a G-deficient rabies virus recombinant: An in vitro and in vivo study. J. Gen. Virol. 81:2147-2153.
8. Faber, M., R. Pulmanausahakul, S. S. Hodawadekar, S. Spitsin, J. P. McGettigan, M. J. Schnell, and B. Dietzschold. 2002. Overexpression of the rabies virus glycoprotein results in enhancement of apoptosis and antiviral immune response. J. Virol. 76:3374-3381.
9. Finke, S., and K. K. Conzelmann. 1999. Virus promoters determine interference by defective RNAs: Selective amplification of mini-RNA vectors and rescue from cDNA by a 3′ copy-back ambisense rabies virus. J. Virol. 73: 3818-3825.
10. Flanagan, E. B., L. A. Ball, and G. W. Wertz. 2000. Moving the glycoprotein gene of vesicular stomatitis virus to promoter-proximal positions accelerates and enhances the protective immune response. J. Virol. 74:7895-7902.
11. Flanagan, E. B., J. M. Zamparo, L. A. Ball, L. L. Rodriguez, and G. W. Wertz. 2001. Rearrangement of the genes of vesicular stomatitis virus eliminates clinical disease in the natural host: New strategy for vaccine development. J. Virol. 75:6107-6114.
12. Foley, H. D., J. P. McGettigan, C. A. Siler, B. Dietzschold, and M. J. Schnell. 2000. A recombinant rabies virus expressing vesicular stomatitis virus glycoprotein fails to protect against rabies virus infection. Proc. Natl. Acad. Sci. USA 97:14680-14685.
13. Gorny, M. K., V. Gianakakos, S. Sharpe, and S. Zolla-Pazner. 1989. Generation of human monoclonal antibodies to human immunodeficiency virus. Proc. Natl. Acad. Sci. USA 86:1624-1628.
14. Jacob, Y., H. Badrane, P. E. Ceccaldi, and N. Tordo. 2000. Cytoplasmic dynein LC8 interacts with lyssavirus phosphoprotein. J. Virol. 74:10217-10222.
15. McGettigan, J. P., H. D. Foley, I. M. Belyakov, J. A. Berzofsky, R. J. Pomerantz, and M. J. Schnell. 2001. Rabies virus-based vectors expressing human immunodeficiency virus type 1 (HIV-1) envelope protein induce a strong, cross-reactive cytotoxic T-lymphocyte response against envelope proteins from different HIV-1 isolates. J. Virol. 75:4430-4434.
16. McGettigan, J. P., S. Sarma, J. M. Orenstein, R. J. Pomerantz, and M. J. Schnell. 2001. Expression and immunogenicity of human immunodeficiency virus type 1 Gag expressed by a replication-competent rhabdovirus-based vaccine vector. J. Virol. 75:8724-8732.
17. Mebatsion, T. 2001. Extensive altenuation of rabies virus by simultaneously modifying the dynein light chain binding site in the P protein and replacing Arg333 in the G protein. J. Virol 75:11496-11502.
18. Mebatsion, T., M. Konig, and K. K. Conzelmann. 1996. Budding of rabies virus particles in the absence of the spike glycoprotein. Cell 84:941-951.
19. Mebatsion, T., F. Weiland, and K. K. Conzelmann. 1999. Matrix protein of rabies virus is responsible for the assembly and budding of bullet-shaped particles and interacts with the transmembrane spike glycoprotein G. J. Virol. 73:242-250.
20. Morimoto, K., H. D. Foley, J. P. McGettigan, M. J. Schnell, and B. Dietzschold. 2000. Reinvestigation of the role of the rabies virus glycoprotein in viral pathogenesis using a reverse genetics approach. J. Neurovirol. 6:373 381.
21. Morimoto, K., D. C. Hooper, H. Carhaugh, Z. F. Fu, H. Koprowski, and B. Dietzschold. 1998. Rabies virus quasispecies: Implications for pathogenesis. Proc. Natl. Acad. Sci. USA 95:3152-3156.
22. Morimoto, K., D. C. Hooper, S. Spitsin, H. Koprowski, and B. Dietzschold. 1999. Pathogenicity of different rallies virus variants inversely correlates inversely correlates with apoptosis and rabies virus glycoprotein expression in infected primary neuron cultures. J. Virol. 73:510-518.
23. Morimoto, K., J. P. McGettigan, H. D. Foley, D. C. Hooper, B. Dietzschold, and M. J. Schnell. 2001. Genetic engineering of live rabies vaccines. Vaccine 19:3543-3551.
24. Poisson, N., E. Real, Y. Gaudin, M. C. Vaney, S. King, Y. Jacob, N. Tordo, and D. Blondel. 2001. Molecular basis for the interaction between rabies virus phosphoprotein P and the dynein light chain LC8: Dissociation of dynein-binding properties and transcriptional functionality of P. J. Gen. Virol. 82:2691-2696.
25. Roux, H., A. Flamand, and D. Blondel. 2000. Interaction of the rabies virus P protein with the LC8 dynein light chain. J. Virol. 74:10212-10216.
26. Roberts, A., L. Buonocore, R. Price, J. Forman, and J. K. Rose. 1999. Attenuated vesicular stomatitis viruses as vaccine vectors. J. Virol. 73:3723-3732.
27. Schnell, M. J., L. Buonocore, E. Boritz, H. P. Ghosh, R. Chernish, and J. K. Rose. 1998. Requirement for a non-specific glycoprotein cytoplasmic domain sequence to drive efficient budding of vesicular stomatitis virus. EMBO J. 17:1289-1296.
28. Schnell, M. J., H. D. Foley, C. A. Siler, J. P. McGettigan, B. Dietzschold, and R. J. Pomerantz. 2000. Recombinant rabies virus as potential live-viral vaccines for HIV-1. Proc. Natl. Acad. Sci. 97:3544-3549.
29. Schnell, M. J., T. Mebatsion, and K. K. Conzelmann. 1994. Infectious rabies viruses from cloned cDNA. EMBO J. 13:4195-4203.
30. Self, I., P. Coulon, P. E. Rollin, and A. Flamand. 1985. Rabies virulence: Effect on pathogenicity and sequence characterization of rabies virus mutations affecting antigenic site III of the glycoprotein. J. Virol. 53:926-934.
31. Slier, C. A., J. P. McGettigan, B. Dietzschold, S. K. Herrine, J. Dubuisson, R. J. Pomerantz, and M. J. Schnell. 2002. Live and killed rhabdovirus-based vectors as potential hepatitis C vaccines. Virology 292:24-34.
32. Wagner, R. R., and J. K. Rose. 1996. Rhabdoviridae: The viruses and their replication, p. 1121-1135. In B. N. Fields, D. M. Knipe, and P. M. Howley (ed.), Fields Virology, 3rd Ed., vol. 1. Lippincott-Raven Publishers, Philadelphia, Pa.
33. Whitt, M., L. Buonocore, C. Prehaud, and J. K. Rose. 1991. Membrane fusion activity, oligomerization, and assembly of the rabies virus glycoprotein. Virology 185:681-688.
34. Yan, X. Y., P. S. Mohankumar, B. Dietzschold, M. J. Schnell, and Z. F. Fu. 2002. The glycoprotein determines the spreading of different rabies virus strains in the CNS. J. Neurovirol. 8:345-352.